Optimal first‐line treatment for advanced thymic carcinoma
| Title: | Optimal first‐line treatment for advanced thymic carcinoma |
|---|---|
| Authors: | Xue Yang, Minglei Zhuo, Anhui Shi, Shengnan Yang, Ziping Wang, Meina Wu, Tongtong An, Yuyan Wang, Jianjie Li, Jia Zhong, Hanxiao Chen, Bo Jia, Zhi Dong, Jun Zhao |
| Source: | Thoracic Cancer, Vol 10, Iss 11, Pp 2081-2087 (2019) |
| Publisher Information: | Wiley, 2019. |
| Publication Year: | 2019 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Chemotherapy, prognosis, radiation therapy, resection, thymic carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background Thymic carcinomas (TCs) are rare aggressive tumors with no standard first‐line treatment. This study was conducted to determine the optimal chemotherapy regimen for advanced TC. Methods This retrospective study included 67 patients treated for stage IV TC in 2006–2015. The primary endpoints were the objective response rate (ORR) and progression‐free survival (PFS) with different chemotherapy regimens. Multivariate Cox regression analysis was used to identify factors associated with PFS, including metastatic status, radiotherapy post‐chemotherapy, primary lesion resection before chemotherapy, and chemotherapy regimen. Results A total of 36 patients received a paclitaxel‐platinum regimen, 31 received a gemcitabine‐platinum regimen, 14 underwent primary lesion resection, and 33 underwent radiotherapy. ORR was 31% (11/36) and 29% (9/31) in the paclitaxel‐platinum and gemcitabine‐platinum groups, respectively (P = 0.890). Median PFS, one‐year PFS rate, and two‐year PFS rate were 7.0 months, 26%, and 6% with paclitaxel‐platinum treatment and 12 months, 48%, and 24% with gemcitabine‐platinum treatment (log‐rank P = 0.030). Median PFS, one‐year PFS rate, and two‐year PFS rate were 18.0 months, 57%, and 33% with surgical resection and 7.3 months, 31%, and 7% without resection (log‐rank P = 0.030). Median PFS, one‐year PFS rate, and two‐year PFS rate were 13.0 months, 52%, and 20% with radiotherapy and 4.3 months, 22%, and 7% without radiotherapy (log‐rank P = 0.001). In multivariate analysis, metastatic status (hazard ratio [HR], 0.33, P = 0.004), surgical resection (HR, 0.32; P = 0.004), and radiotherapy (HR, 0.32; P |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1759-7714 1759-7706 |
| Relation: | https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714 |
| DOI: | 10.1111/1759-7714.13181 |
| Access URL: | https://doaj.org/article/c17084a95c5e4671a8831f44dced703c |
| Accession Number: | edsdoj.17084a95c5e4671a8831f44dced703c |
| Database: | Directory of Open Access Journals |
| ISSN: | 17597714 17597706 |
|---|---|
| DOI: | 10.1111/1759-7714.13181 |
| Published in: | Thoracic Cancer |
| Language: | English |